Business Overview: Arbutus Biopharma Corporation (Nasdaq: ABUS)

---

Executive Summary

Arbutus Biopharma is a clinical-stage biopharmaceutical company pursuing a functional cure for chronic hepatitis B (HBV) through its lead candidate imdusiran (AB-729), while simultaneously monetizing a valuable, decades-old lipid nanoparticle (LNP) delivery patent portfolio through licensing and litigation. The company's profile changed dramatically in March 2026 with a landmark $2.25 billion global patent settlement with Moderna, resolving litigation over LNP technology used in Moderna's COVID-19 vaccine — a case that validates Arbutus's foundational LNP intellectual property and provides a substantial, if partly contingent, cash windfall.

Fiscal 2025 revenue was $14.1 million (up from $6.2 million in 2024, driven by recognition of deferred Qilu Pharmaceutical partnership revenue), with a net loss of $33.5 million ($0.17/share), a meaningful improvement from the $69.9 million loss in 2024. The company held $91.5 million in cash and marketable securities at year-end 2025 — a figure set to be transformed by the Moderna settlement's $950 million noncontingent payment due in July 2026 (Arbutus receives 20% of that payment after litigation costs, plus retains roughly 16% equity in licensee Genevant Sciences).

---

Core Business Model

Arbutus operates two distinct, complementary business lines. First, it is a clinical-stage drug developer advancing imdusiran and related HBV pipeline assets toward a functional cure, using its proprietary GalNAc-conjugate subcutaneous delivery technology. Second — and increasingly significant — it is an IP licensor and litigant, monetizing foundational lipid nanoparticle (LNP) patents (exclusively licensed to Genevant Sciences, in which Arbutus holds an equity stake) that underpin mRNA-vaccine and RNAi-therapeutic delivery across the industry, including Moderna's and Pfizer/BioNTech's COVID-19 vaccines and Alnylam's RNAi drugs.

---

Business Segments

• Hepatitis B Therapeutics (Imdusiran/AB-729): An RNAi therapeutic using GalNAc-conjugate delivery, in Phase 2a and long-term follow-up studies for chronic HBV, targeting "functional cure" (sustained HBsAg seroclearance and undetectable HBV DNA off treatment) — 10 patients have achieved this milestone to date, with two more reaching it recently during extended monitoring, and the FDA has granted imdusiran Fast Track designation.
• LNP Licensing & Litigation: Foundational lipid nanoparticle delivery patents licensed to Genevant Sciences, generating royalty revenue (e.g., from Alnylam's ONPATTRO and pipeline products) and, more dramatically, high-value patent infringement settlements and ongoing litigation (Moderna settlement; active Pfizer/BioNTech litigation with a favorable September 2025 claim-construction ruling).

---

Product Portfolio

Arbutus has no approved, marketed drug products. Its clinical portfolio centers on imdusiran for chronic HBV, alongside earlier-stage pipeline candidates leveraging the same GalNAc delivery platform. Its "product" on the licensing side is intellectual property itself — foundational LNP delivery patents that other companies' marketed mRNA vaccines and RNAi drugs depend on, which is why the Moderna litigation outcome and ongoing Pfizer/BioNTech case are financially consequential despite Arbutus having no vaccine products of its own.

---

Competitive Landscape

Arbutus operates in two very different competitive contexts:

• In hepatitis B therapeutics, it competes with other companies pursuing HBV functional-cure strategies, including Gilead Sciences, GSK, Vir Biotechnology, and Assembly Biosciences, all racing toward RNAi, capsid-assembly-modulator, or immunomodulatory approaches to achieve durable HBV suppression or cure.
• In LNP intellectual property, Arbutus (via Genevant) essentially holds leverage over major mRNA-vaccine and RNAi-drug makers (Moderna, Pfizer/BioNTech, Alnylam) that rely on LNP delivery technology, making its "competitors" here really licensees/defendants rather than product-market rivals.

---

Strategic Strengths & Risks

Strengths

• Landmark Moderna settlement: $2.25 billion in aggregate potential payments (a $950 million noncontingent tranche due July 2026, plus a $1.3 billion contingent tranche) both validates Arbutus's foundational LNP patents and provides transformative near-term liquidity, with management signaling intent to return capital to shareholders.
• Active, favorably-positioned Pfizer/BioNTech litigation: a September 2025 claim-construction ruling viewed favorably by the company keeps a second major settlement/damages opportunity alive.
• Clinical progress toward HBV functional cure: 10+ patients achieving functional cure in Phase 2a/follow-up studies is a meaningful proof-of-concept for imdusiran, alongside FDA Fast Track designation.
• Improving core financial trajectory: net loss narrowed substantially year-over-year even before accounting for the Moderna settlement proceeds.

Risks

• Contingent payment risk: $1.3 billion of the Moderna settlement depends on the outcome of an appellate ruling on Section 1498 federal sovereign-immunity doctrine, meaning a meaningful portion of the headline settlement value is not guaranteed.
• Ongoing litigation risk and cost: the Pfizer/BioNTech case remains unresolved and litigation is inherently uncertain and costly, even with a favorable interim ruling.
• Clinical-stage pipeline risk: imdusiran remains in Phase 2a/follow-up, with Phase 3 and regulatory approval still ahead; HBV functional cure has proven elusive industry-wide despite years of R&D investment across multiple companies.
• Reliance on non-recurring, litigation-driven revenue: absent further settlements or licensing wins, Arbutus's core royalty revenue (declining alongside Alnylam's ONPATTRO sales) is a small and shrinking base relative to its cost structure.

---

Financial Overview

Arbutus's share of the noncontingent Moderna payment is 20% after litigation cost deduction, alongside its roughly 16% equity stake in Genevant Sciences, the exclusive LNP licensee.

---

Summary Conclusion

Arbutus Biopharma has been transformed by the March 2026 Moderna settlement, which both validates its foundational lipid nanoparticle patent estate and promises a substantial near-term cash inflow, with the Pfizer/BioNTech litigation offering a further potential catalyst. Underneath the headline litigation news, the company continues to advance imdusiran toward a hepatitis B functional cure with encouraging, if still early-stage, clinical results. The investment case now combines a well-funded, de-risked balance sheet (post-settlement) with genuine, if unproven, clinical-stage upside in HBV — a considerably different risk profile than a typical clinical-stage biotech reliant solely on binary trial outcomes.